Synthesis, Spectral Analysis and Biological Potency of Hydrazoneoxime Ligands Incorporating Pyrazolone Moiety and their Metal Complexes
Nursabah Sarıkavaklı1*, Emrah Koç1
, Meshari M.H. Aljohani2
and Syed Khalid Mustafa2
1Department of Chemistry, Faculty of Arts and Sciences, Aydın Adnan Menderes University,09010, Aydın-Turkey.
2Department of Chemistry, Faculty of Sciences, University of Tabuk, Kingdom of Saudi Arabia. .
Corresponding Author E-mail: nsarikavakli@adu.edu.tr
DOI : http://dx.doi.org/10.13005/ojc/360626
Article Received on : 10-10-2020
Article Accepted on : 10-12-2020
Article Published : 30 Dec 2020
A modest attempt has been made for the synthesis of hydrazoneoxime ligands bearing pyrazolone group (1-4) and their successive metal complexes such as: 1(a-c), 2(a-c), 3(a-c) and 4(a-c). The precursor (1Z,2E)-2-(hydroxyimino) ethanehydroximohydrazide (GH2) was obtained throughcoupling of (1Z,2E)-N-hydroxy-2-(hydroxyimino) ethanimidoyl chlorideand hydrazinium hydroxideto generate hydrazonoxime compounds bearing the pyrazolone group. The ligands (1-4) were were reactedwith MX2.nH2O, where M = Co(II), Ni(II), and Cu(II) to obtain the successive metal coordinated compounds into good yields. Theligands and their metal complexeswere investigated byusing 1HNMR, 13CNMR, FT-IR, elemental analysis, and magnetic susceptibility measuremented.Tautomerism in the ligands is investigated spectroscopically and biological activities are evaluated as well. Finally, the findings of present study were found within good egreement with other worker.
KEYWORDS:Biological Activities; Hydrazoneoxime; Metal complexes; Pyrazolone; Spectral studies; Tautomerism
Download this article as:Copy the following to cite this article: Sarıkavaklı N, Koç E, Aljohani M. M. H, Mustafa S. K. Synthesis, Spectral Analysis and Biological Potency of Hydrazoneoxime Ligands Incorporating Pyrazolone Moiety and Their Metal Complexes. Orient J Chem 2020;36(6). |
Copy the following to cite this URL: Sarıkavaklı N, Koç E, Aljohani M. M. H, Mustafa S. K. Synthesis, Spectral Analysis and Biological Potency of Hydrazoneoxime Ligands Incorporating Pyrazolone Moiety and Their Metal Complexes. Orient J Chem 2020;36(6). Available from: https://bit.ly/3nk2wRb |
Introduction
Pyrazolone is considered as an importantcomponent or structural unit which is present in variousactive compounds. Owing toits convenient synthesis as well asversatile biological applications particularly itscomprehensive antisepsis , antitumor, antibacterial action[1-4],pyrazolone and its complexes have acquired a significant consideration in coordination as well as in medicinal chemistry.
Pyrazolonederived productsare paramountkind of heterocyclic compounds that occurs in various drugsas well as in synthetic products [5,6]. These compoundsshowextraordinary analgesic [7], antitubercular [8], antifungal, antibacterial [9], anti-inflammatory [10], antioxidant and antitumor activities [11]. Because of their facile synthesis and characteristicbiological activity, pyrazolone arrangement performs a significant function and reflects an effectiveexample for combinatorial and pharmaceutical chemistry. Furthermore, pyrazole derived products showedoutstandingbiological asset,for example, anti-microbial [12], analgesic [13], anti-inflammatory [14], and anticancer activities [15]. This provided anenormous boost to explore for potentially active compounds having pyrazole substituents.
Herein, the derivatization of hydrazoneoxime ligands bearing pyrazolone group (1-4) and their metal complexes1(a-c), 2(a-c), 3(a-c),4(a-c)was reported. The ligands and its complexes were characterized by1H NMR, 13C NMR, FT-IR spectroscopy, elemental analysis ,and magnetic susceptibility techniques. The proposed general structure of the ligand is given in Scheme.1
Scheme 1: The moleculer formules of the ligands. |
Experimental
Instruments and reagents
Reagentsused in the experiment have been obtained from Sigma-Aldrich, Merck, and Fluka and were handled as received. Themelting point of the synthesised complexes and the ligands were varified and calculated bythe Büchi SMP-20 apparatus using an open capillary method.For the calculation of FT-IR spectra , KBr discs on a Perkin Elmer Mattson 1000 spectrophotometer were used, 1H and 13C NMR spectra have been reported by Bruker-Spectrospin Avance DTX 400 Ultra-Shield in deuterated dimethylsulphoxide (DMSO-d6) and tetramethylsilane (TMS) used as an internal standard and chemical shifts considered in ppm.The Leco CHNS-932 analyzer used for the elemental analysis: and for the pH measurements,an Orion Expandable Ion Analyzer EA 940 was used. The melting point , colors ,molecular weights, percentage of yield, molar conductance, magnetic susceptibilities (Sherwood Scientific) have been calculated, and are given in the following sections.
Preparation of the ligands and their nomenclature
The precursor (1Z,2E)-2-(hydroxyimino) ethanehydroximohydrazide (GH2) was prepared by the action of the (1Z,2E)-N-hydroxy-2-(hydroxyimino) ethanimidoyl chloride [16] and hydrazinium hydroxide.Since the parent compound , GH2 is unstable at normal temperature,so it was utilized without further purification or as it was received.Hydrazoneoxime ligands bearing pyrazolone group (1-4)have beenprepared with the5-pyrazolones as mentioned in the literature [17] and characterized their structuresby using spectral techniques.
The IUPAC name of the ligands may be given as 2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino) etanimidoil]-5-metil-4-[(Z)-fenildia zenil]-2,4-dihidro-3H-pirazol-3-on (1), 2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino) etanimidoil] -5-metil-4-[(Z)-(4-nitrofenil) diazenil]-2,4-dihidro-3H-pirazol-3-on (2), 2-[(1Z,2E)-N-hydro kis-2-(hydrokisimino) etanimidoil]-4-[(Z)-(4-metoksifenil) diazenil]-5-metil-2,4-dihidro-3H-pirazol-3-on (3) and 2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino) etanimidoil]-5-metil-4-[(Z)-(4-metilfenil)diazenil]-2,4-dihidro-3H-pirazol-3-on (4). The preparation procedures were followed as given in theliterature [18-20]. For the synthesis of (1-4) the common route follows as given in theS cheme 2.
Scheme 2: General route for the synthesis of ligands (1-4) |
General procedure of synthesis
Synthesis of hydrazoneoxime ligands bearing pyrazolone group(1-4)
Aniline derivatives 10 mmol (0.69 g, aniline; 1.38 g, 4-nitroaniline; 1.23 g, p-anisidine; or 1.04 g, p-toluidine respectively)were taken and dissolved in a mixture of 1:1 ratio of glacial Acetic acid and concentrated Hydrochloric acid (20 mL),and cooled the solutionupto 0–5 °C.Sodium nitrite (0.69g or 0.01 mol) was taken and dissolved in 10mL water, and then added dropwise to the above-prepared solution mixturewith vigorous stirring for nearly one hourto maintain the solution temperature between 0–5 °C. The obtained diazonium solution has been mixed in aliquots for 30 minutes, to thesolution of 2-[(1Z,2Z)-N-hydrokis-2-(hydrokisimino)etanimidoil]-5-metil-2,4-dihidro-3H-pirazol-3-on (0.76 g or 0.01 mol) in 10 mL of ethyl alcohol ,and stirred vigorously , added the NaOH solution for maintaining the pH level between(7–8). The mixture has bee stirred for 2 hoursand maintain the solution temperature between 0–5 °C. Theobtained product was separated by means of diluting with water (50 mL), filtered, washed several times withdistilled water, and finally dried.
2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino)etanimidoil]-5-metil-4-[(Z)-fenildiazenil] -2,4-dihidro-3H-pirazol-3-on(1)
The analytical and physical properties of the ligand (1) and its metal complexes (1a-1c) are provided in Table 1. Appearance: yellow powder; Yield=87%, m.p.(decomp.) 165 °C; The reaction scheme is given in Scheme 2. The compound is soluble in commonly used solvents likeCH2Cl2, CHCl2, DMF, EtOH and DMSO. Anal. Calcd. for C12H12N6O3 (288.27 g mol−1): 50.00 % C; 4.20 % H; 29.15 % N, Found: 50.60 % C; 4.40 % H; 29.21 % N. The infrared spectral data of the ligand (1) is given in Table 2.FT-IR (KBr, νmax/cm-1): 3271 (N-H), 3681(O-H), 2970 (C-HArom.), 2844 (C-HAliph.), 1598-1664 (C=NOxim.), 1556 (C=NHydr.), 1033(N-O), 1484 ve 1441 (N-NAzo.). The FT-IR spectrum of ligand (1) is given in Figure 1.1H NMR peaks (DMSO-d6, (ઠ) ppm): 2,18(s,3H, pyazolone-CH3); 7.17-7.57 (m,5H, Ar-H ); 11.81; 12.20 (d, 2H (OH); 7.84 (s, 2H, CH=NOH); 13.01 (s, 2H -CH=N-NH); 11.81; 12.20 (s, 4H (OH); 7.84 s, 2H (CH=NOH), 7.39; 7.40; 7.42 t, 7.55; 7.57 d, 7.17; 7.18; 7.20 t; 4H (Ar-H), 13.01 s, 2H (-CH=N-NH).13C NMR peaks of the compound: (CDCl3, TMS, ઠ ppm):148.35(N-C=N-OH); 148.80(CH=N-OH); 156.99 (C=N-N);12.03 (CH3); 158.17 (C=N-NH);159.76 (C=O); 129.96, 116.68, 126.05, 142.80 (Ar-C).
Table 1: Physical and analytical data of the hydrazoneoxime lıgand (1) bearıng pyrazolone group and its complexes
Compound |
Molecula Composition |
M.W. (g/mol) |
Apperance |
Melting Point (d)* (ºC) |
Yield (%) |
Calculated (Found) % |
||
C |
H |
N |
||||||
Ligand (1) |
C12H12N6O3 |
288,27 |
Yellow |
165 |
87 |
50,00 (50,60) |
4,20 (4,40) |
29,15 (29,21) |
Complex(1a) |
C24H22N12O6Ni |
633,21 |
Red-brown |
>370 * |
52 |
45,52 (45,60) |
3,50 (3,43) |
26,54 (26,47) |
Complex(1b) |
C24H22N12O6Co |
633,45 |
Dark-brown |
230 * |
76 |
45,51 (45,58) |
3,50 (3,43) |
26,53 (26,44) |
Complex(1c) |
C24H22N12O6Cu |
638,06 |
Dark-brown |
193 * |
68 |
45,18 (45,59) |
3,48 (3,55) |
26,34 (25, 77) |
Figure 1: FT-IR spectrum of ligand (1) |
Table 2: Infrared data for the ligand(1) and its complexes
Compound |
ν(O-H) |
ν(N-H) |
ν(C=O) |
ν(C=N)oxim |
ν(C=N)hyd. |
ν(CH)Arom. |
ν(CH)Alip. |
ν(N-N) |
ν(N-O) |
ν (OH―O) |
Ligand (1) |
3681w |
3271w |
1667s |
1598-1664m |
1536-1556m |
2970m |
3088m |
1484-1441m |
1033m |
– |
Complex(1a) |
3271m |
3271m |
1667w |
1594-1677m |
1536-1556m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(1b) |
3271m |
3271m |
1667w |
1594-1677m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
|
Complex(1c) |
3168m |
3168m |
1655m |
1594-1677m |
2970m |
2864m |
1449-1484m |
1033m |
1738m |
2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino)etanimidoil]-5-metil-4-[(Z)-(4-nitrofenil) diazenil]-2,4-dihidro-3H-pirazol-3-on (2)
Some important characteristics (analytical and physical)of the synthesized ligand (2) and its metal complexes (2a-2c) are givem in Table 3. Appearance: Dark brown powder; Yield=75 %, M.p.(decomposition) 250 °C;For the synthesis of the compound (2), reaction arrangements are illustrated in Scheme 2. This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO. Anal. Calcd. for C12H11N7O5 (333.27 g mol−1): 43.25 % C; 3.33 % H; 29.42 % N, Found: 43.83 % C; 3.40 % H; 29.35 % N. The infrared spectral collected statistics of the ligand (2)are revealed inTable 4. FT-IR (KBr, νmax/cm-1): 3271 (N-H), 3681(O-H), 2970 (C-HArom.), 2864 (C-HAliph.), 1609-1677 (C=NOxim), 1543 (C=NHydr.), 1033(N-O), 1506 ve 1483 (N-NAzo), 1417 ve 1376 (-NO2). The FT-IR spectrum of ligand (2) is given in Figure 2. 1H NMR peaks (DMSO-d6, (ઠ) ppm): 2,20 (s, 3H, pyazolone-CH3 ); 7.68-7.78 (m,4H, Ar-H); 11.84; 12.22 (d, 2H (OH); 7,85 (s, 2H, CH=NOH); 13.03 (s, 2H -CH=N-NH).13C NMR peaks of the compound: (CDCl3, TMS, (ઠ) ppm): 149.18 (N-C=N-OH); 147.47 (CH=N-OH); 157.40 (C=N-N); 12.07 (CH3); 156.19(C=N-NH); 158.05 (C=O); 116.89, 125.86, 129.41, 136.99 (Ar-C).
Table 3: Physical and analytical data of the hydrazoneoxime lıgand (2) bearıng pyrazolone group and its complexes
Compound |
Molecula Composition |
M.W. (g/mol) |
Apperance |
Melting Point (d)* (ºC) |
Yield (%) |
Calculated (Found) %
C H N |
||
Ligand (2) |
C12H11N7O5 |
333,26 |
Light-brown |
250 |
75 |
43,25 (43,83) |
3,33 (3,40) |
29,42 (29,35) |
Complex(2a) |
C24H20N14O10Ni |
723,21 |
Red-brown |
240 * |
80 |
39,86 (39,93) |
2,79 (2,85) |
27,12 (27,69) |
Complex(2b) |
C24H20N14O10Co |
723,45 |
Dark-brown |
200 * |
76 |
39,85 (39,27) |
2,79 (3,34) |
27,11 (27,67) |
Complex(2c) |
C24H20N14O10Cu |
728,06 |
Dark-brown |
195 * |
65 |
39,59 (39,99) |
2,77 (2,83) |
26,93 (26,99) |
Figure 2: FT-IR spectrum of ligand (2) |
Table 4: Infrared data for the ligand (2) and its complexes
Compound |
ν(O-H) |
ν(N-H) |
ν(C=O) |
ν(C=N)oxim |
ν(C=N)hyd. |
ν(CH)Arom. |
ν(CH)Alip. |
ν(N-N) |
ν(N-O) |
ν (OH―O) |
Ligand (2) |
3681w |
3271w |
1667s |
1598-1664m |
1536-1556m |
2970m |
3088m |
1484-1441m |
1033m |
– |
Complex(2a) |
3271m |
3271m |
1667w |
1594-1677m |
1536-1556m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(2b) |
3271m |
3271m |
1667w |
1594-1677m |
1536-1556m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(2c) |
3168m |
3168m |
1655m |
1594-1677m |
1536-1556m |
2970m |
2864m |
1449-1484m |
1033m |
1738m |
2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino)etanimidoil]-4-[(Z)-(4-metoksifenil) diazenil]-5-metil-2,4-dihidro-3H-pirazol-3-on (3)
Some important characteristics (analytical and physical) of the synthesized ligand (3) and its metal complexes (3a-3c) are given in Table 5. Appearance: Red powder; Yield=83 %, M.p.(decomposition) 230 °C;For the synthesis of the compound (3),reaction arrangements are illustrated in Scheme 2.This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO. Anal. Calcd. for C13H14N6O4 (318.29 g mol−1): 49.06 % C; 4.43 % H; 26.40 % N, Found: 49.13 % C; 4.37 % H; 26.48 % N. The infrared spectral collected statisticsof the ligand (3) are revealed inTable 6. FT-IR (KBr, νmax/cm-1): 3235 (N-H), 3681 (O-H), 2970 (C-H Arom.), 2844 (C-H Aliph.), 1595-1648 (C=NOxim), 1553 (C=N Hydr.), 1033 (N-O), 1454 ve 1474 (N-NAzo), 1738 –C=O. The FT-IR spectrum ofligand (3) is can be seen in Figure 3. 1H NMR peaks (DMSO-d6, (ઠ) ppm): 2.16 (s,3H, pyazolone-CH3 ); 6.98 -7.52 (m,4H, Ar-H); 12.17-12.21 (d, 2H (OH); 7.83 (s, 2H, CH=NOH); 13.07 (s, 2H -CH=N-NH); 3,74 (s, 3H –OCH3.13C NMR peaks of the compound: (CDCl3, TMS, (ઠ) ppm): 148.62 (N-C=N-OH); 144.97 (CH=N-OH); 157.97 (C=N-N); 12.04 (CH3); 157.26 (C=N-NH); 158.35 (C=O); 115.28, 118.28, 148.62, 135.27 (Ar-C); 55.89 (OCH3).
Table 5: Physical and analytical data of the hydrazoneoxime lıgand(3) bearing pyrazolone group and its complexes
Compound |
Molecula Composition |
M.W. (g/mol) |
Apperance |
Melting Point (d)* (ºC) |
Yield (%) |
Calculated (Found) % |
||
C |
H |
N |
||||||
Ligand (3) |
C13H14N6O4 |
318,29 |
Red |
230 |
83 |
49,06 (49,13) |
4,43 (4,37) |
26,40 (26,48) |
Complex(3a) |
C26H26N12O8Ni |
693,6 |
Red-brown |
>370 * |
78 |
45,05 (45,13) |
3,78 (3,72) |
24,25 (24,32) |
Complex(3b) |
C26H26N12O8Co |
693,50 |
Dark-brown |
>350 * |
65 |
45,03 (45,09) |
3,78 (3,72) |
24,24 (24,17) |
Complex(3c) |
C26H26N12O8Cu |
698,12 |
Dark-brown |
196* |
68 |
44,73 (44,79) |
3,75 (3,68) |
24,08 (24,66) |
(d)*: decomposition
Figure 3: FT-IR spectrum of ligand (3) |
Table 6: Infrared data for the ligand(3) and its complexes
Compound |
ν(O-H) |
ν(N-H) |
ν(C=O) |
ν(C=N)oxim |
ν(C=N)hyd. |
ν(CH)Arom. |
ν(CH)Alip. |
ν(N-N) |
ν(N-O) |
ν (OH―O) |
Ligand (3) |
3681w |
3271w |
1667s |
1598-1664m |
1536-1556m |
2970m |
3088m |
1484-1441m |
1033m |
– |
Complex(3a) |
3271m |
3271m |
1667w |
1594-1677m |
1536-1556m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(3b) |
3271m |
3271m |
1667w |
1594-1677m |
– |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(3c) |
3168m |
3168m |
1655m |
1594-1677m |
– |
2970m |
2864m |
1449-1484m |
1033m |
1738m |
2-[(1Z,2E)-N-hydrokis-2-(hydrokisimino)etanimidoil]-5-metil-4-[(Z)-(4-metilfenil) diazenil]-2,4-dihidro-3H-pirazol-3-on (4)
Some important characteristics (analytical and physical) of thesynthesized ligand(4),and more (4a-4c)it’s metal complexes are collected in Table 7. Appearance: Light brown powder: Yield=76 %, M.p.(decomposition) 243 °C;For the synthesis of the compound (4),reaction arrangements are illustrated in Scheme 2. This compoundis soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO. Anal. Calcd. for C13H14N6O3 (302.29 g mol−1): 51.65 % C; 4.67 % H; 27.80 % N, Found: 51.70 % C; 4.67 % H; 27.80 % N. The infrared spectral collected statisticsof the ligand (4) are revealed inTable 8. FT-IR (KBr, νmax/cm-1):3168 (N-H), 3681(O-H), 2970 (C-HArom.), 2844 (C-H Aliph.), 1594-1669 (C=NOxim.), 1536 (C=N Hydr.), 1033(N-O), 1492 ve 1449 (N-NAzo.), 1738 –C=O, 2970 –CH3(phenil) ve CH3(methyl). The FT-IR spectrum of ligand (4) is given in Figure 4.1H NMR peaks (DMSO-d6, (ઠ) ppm): 2.17 (s,3H, pyazolone-CH3 ); 7.18-7.46 (m,4H, Ar-H); 11.76; 12.18 (d, 2H (OH); 7,83 (s, 2H, CH=NOH); 13.05 (s, 2H -CH=N-NH); 2.27 (s, 3H –CH3(fenil).13C NMR peaks of the compound: (CDCl3, TMS, (ઠ) ppm): 148.67 (N-C=N-OH); 148.20 (CH=N-OH); 158.30 (C=N-N); 12.02 (CH3); 157.12 (C=N-NH); 160.64 (C=O); 116.69, 126.24, 130.42, 135.68 (Ar-C); 20.97 (CH3).
Table 7: Physical and analytical data of the hydrazoneoxime lıgand(4) bearıng pyrazolone group and its complexes
Compound |
Molecula Composition |
M.W. (g/mol) |
Apperance |
Melting Point (d)* (ºC) |
Yield (%) |
Calculated (Found) % |
||
C |
H |
N |
||||||
Ligand (4) |
C13H14N6O3 |
302,29 |
Dark-yellow |
243 |
76 |
51,65 (51,70) |
4,67 (4,71) |
27,80 (27,74) |
Complex(4a) |
C26H26N12O6Ni |
661,27 |
Red-brown |
>370 * |
72 |
47,23 (47,16) |
3,96 (3,89) |
25,42 (25,36) |
Complex(4b) |
C26H26N12O6Co |
661,51 |
Dark-brown |
230 * |
70 |
47,21 (47,28) |
3,96 (3,89) |
25,41 (25,57) |
Complex(4c) |
C26H26N12O6Cu |
666,12 |
Dark-brown |
195* |
64 |
46,88 (46,81) |
3,93 (3,88) |
25,23 (27,17) |
(d)*: decomposition
Figure 4: FT-IR spectrum of ligand (4) |
Table 8: Infrared data for the ligand(4) and its complexes
Compound |
ν(O-H) |
ν(N-H) |
ν(C=O) |
ν(C=N)oxim |
ν(C=N)hyd. |
ν(CH)Arom. |
ν(CH)Alip. |
ν(N-N) |
ν(N-O) |
ν (OH―O) |
Ligand (4) |
3681w |
3271w |
1667s |
1598-1664m |
1536-1556m |
2970m |
3088m |
1484-1441m |
1033m |
– |
Complex(4a) |
3271m |
3271m |
1667w |
1594-1677m |
1536-1556m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(4b) |
3271m |
3271m |
1667w |
1594-1677m |
1536-1556m |
2970m |
2844m |
1449-1484m |
1033m |
1738m |
Complex(4c) |
3168m |
3168m |
1655m |
1594-1677m |
1536-1556m |
2970m |
2864m |
1449-1484m |
1033m |
1738m |
Compound’s Synthesis
For the synthesis of all three complexes , a general method was used [16]: The 2 mmol of the above ligands, (1-4), were dissolved in 10 mL absolute ethyl alcohol at refluxing temperature. A solution of NiCl2.6H2O or CuCl2.2H2O or CoCl2.6H2O (1 mmol) with water (15 ml) is taken,and then mixed dropwise over the ligand solutionwith vigorous stirring, a noticeable color change as well as a reduction in the pH value (~3.0–3.5) was observed. Sodium hydroxide (1%) in water (20 mL) has been mixed to adjust the pH ~5–5.5, and maintainedthe temperature of the reaction mixture nearly to room temperature.Mixtures have been stirred by the hour at 50 °C on a water bath so as to ensure complete precipitation of complexes. After one hour the precipitated solid has been filtered, washed by means of hot ethanol (3×5 ml),also dehydrated in vacuo, over anhydrous CaCl2.
Proposed structures for the monomeric Co(II), Ni(II) Cu(II) as well as the ligands (1-4) are given in Scheme 3.
Scheme 3: Structure of the metal complexes |
Appearance:Red-brown powder, Yield=52%, M.p.(decomp.)>370°C; This compoundis soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C24H22N12O6Ni (633.21 g mol−1): 45.52 % C; 3.50 % H; 26.54 % N, Found: 45.60 % C; 3.43% H; 26.47 % N. FT-IR (KBr, νmax/cm-1): 3271 (N-H), 3681(O-H), 2970 (C-HArom.), 2864 (C-HAliph.), 1609-1677 (C=NOxim), 1543 (C=NHydr.), 1033(N-O), 1506 ve 1483 (N-NAzo), 1417 ve 1376 (-NO2).
Appearance:Dark brown powder, Yield=76%, M.p.(decomp.)>230°C; This compoundis soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C24H22N12O6Co (633,45 g mol−1): 45.51 % C; 3.50 % H; 26.53 % N, Found: 45.58 % C; 3.43% H; 26.44 % N.
Appearance:Dark brown powder, Yield=68%, M.p.(decomp.)>193°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C24H22N12O6Cu: (638,06 g mol−1): 45.18 % C; 3.48 % H; 26.34 % N, Found: 45.59 % C; 3.55% H; 25.77 % N.
Appearance:Red-brown powder, Yield=80%, m.p.(decomp.)>240°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C24H20N14O10Ni (723.21 g mol−1): 39.86 % C; 2.79 % H; 27.11 % N, Found: 39.93 % C; 2.85% H; 27.69 % N.
Appearance:Dark-brown powder, Yield=76%, M.p.(decomp.)>200°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C24H20N14O10Co (723.45 g mol−1): 39.85 % C; 2.79 % H; 27.11 % N, Found: 39.27 % C; 3.34% H; 27.67 % N.
Appearance:Dark-brown powder, Yield=65%, M.p.(decomp.)>195°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C24H22N12O6Cu (728,06 g mol−1): 39.59 % C; 2.77 % H; 26.93 % N, Found: 39.99 % C; 2.83% H; 26.99 % N.
Appearance:Red-brown powder, Yield=78%, M.p.(decomp.)>370°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C26H26N12O8Ni (793,60 g mol−1): 45.05 % C; 3.78 % H; 24.25 % N, Found: 45.13 % C; 3.72% H; 24.32 % N.
Appearance:Dark-brown powder, Yield=65%, M.p.(decomp.)>350°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C26H26N12O8Co (793,50 g mol−1): 45.03 % C; 3.78 % H; 24.24 % N, Found: 45.09 % C; 3.72 % H; 24.17% N.
Appearance:Dark-brown powder, Yield=68%, M.p.(decomp.)>196°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C26H26N12O8Cu (798,12 g mol−1): 44,73 % C; 3,68 % H; 24,08 % N, Found: 44,79 % C; 3,68 % H; 24,66 % N.
Appearance:Red-brown powder, Yield=72 %, M.p.(decomp.)>370°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH, and DMSO.Anal. Calcd. for C24H20N14O10Ni (661,27 g mol−1): 47.23 % C; 3.96 % H; 25.42 % N, Found: 45.16 % C; 3.89 % H; 25.36 % N.
Appearance:Dark-brown powder, yield (70 %), M.p.(decomp.)>230°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C26H26N12O8Co (661,51 g mol−1): 47.21 % C; 3.96 % H; 25.42 % N, Found: 47.28 % C; 3.89 % H; 25.57 % N.
Appearance:Dark-brown powder, Yield=64 %, M.p.(decomp.)>195°C; This compound is soluble in commonly used solvents like CH2Cl2, CHCl2, DMF, EtOH and DMSO.Anal. Calcd. for C26H26N12O8Cu (666,12 g mol−1): 46.88 % C; 3.93 % H; 25.23 % N, Found: 46.81 % C; 3.88 % H; 27.17 % N.
In vitroantimicrobic activity
The antimicrobic activity of the test compounds was evaluated by way of agar well diffusion method [21-22]. 0.1mL of the diluted inoculums (106 CFU/mL) of test organisms are taken and spread on NA/SDA (Nutrient agar/ Sabouraud dextrose agar) plates. Wells of 6 mm diameter have been punctured into the agar medium and filled one byone with 150mL of compound(150 µg/L) solvent blank and an antibiotic (chloramphenicol,100 µg/L) to which the test the sensitivity of bacteria. Fluconazole at the concentration of 100µg/L has been applied for the monitor versus Candida albicans, Candida tropicalis, and Candida glabrata. The plates were in cubated for at 37°C 24 hours. Antimicrobial activity was has been assessed in order to the zone of inhibition versus the test organism.
Results and Discussion
Spectral studies: structure of ligands and complexes
Synthesis of new hydrazoneoxime ligands bearing pyrazolone group (1-4) that were prepared by reaction of (1Z,2E)-N-hydroxy-2-(hydroxyimino) ethanimidoyl chloride [16-17] with hydrazinium hydroxideand their metal complexes1(a-c), 2(a-c), 3(a-c),4(a-c)were reported (Scheme 2 and 3). The ligands used in this work were prepared using the literature mentioned elsewhere [18-20]. The atomic arrangement of the synthesized ligands (1-4)including their metal complexes were establishedon the basis of theirelemental analysis, FI-TIR,1H NMR, 13C NMR,along with thecalculation of their magnetic susceptibility as well.The analytical andphysical propertiesof the prepared ligands including their metal complexes besummarisedintoTables 1,3,5,along with7.
The FT-IRspectrum related to thesynthesized ligands(1-4) as well as its metal complexes1(a-c), 2(a-c), 3(a-c) and 4(a-c). 1-4 and 1(a-c), 2(a-c), 3(a-c), and 4(a-c) exhibited a carbonyl (keto) band at 1655-1667 cm-1, and NH band (hydrazo) at 3168-3271 cm-1 as shown in the IR spectral data of the representative ligand (1) (Fig.1).The IR frequencies of the representative ligand and its complexes are shown in Table 1. The IRspectralcollected statistics of the synthesized metal complexes has to begiven intoTables 2,4,6,and8. Such saidvalues indicated that eachcomplexes are exist in keto-hydrazo form (T2), as well as in solid-state[23-25]
The 1H NMR spectra of all ligands (1-4)in DMSO-d6showed a single peak lying between 2.16-2.20 ppm corresponding to methyl protons (pyrazolone-CH3)at. The 1H NMR spectral data of ligand (3)indicated a singlet for methoxy protons (Ph-OCH3 ) at 3.74 ppm while another singlet for methyl protons (Ph-CH3) at 2.27 ppm. The 1H NMR spectra of all the ligands (1-4) showed multiple peak at between 6.98-7.78 ppm for aromatic protons (Ar-H). The 1H NMR spectra of all ligands (1-4) also showed a single peaks for (CH=NOH) protons lying in the range of7.83-7.85 ppm. They also exhibited a doublet for the characteristic oxime OH protons(OH)in the range 11.76-12.22 ppm. Such chemical shift shave to be distinctive values,favour hydra zones and oximes, that help in to ascertain the proposed structure [16,25].
The possible tautomeric forms of compounds (1-4)as indicated inScheme 4.The compounds possibly be present in four likly tautomeric models i.e. keto-azo (T1 and T4), keto-hydrazo (T2),as well asenol-azo (T3). In accordance with the literature, better stabilizet automeric model exist in theketo-hydrazo form (T2).It may be due to the presence of the intra molecular O—H bond. It is known that the existence of an intra molecular hydrogen bonding can show the stability of compounds in corresponding tautomeric form. The result is consistent with the literature [23,26-29].
Scheme 4: Tautomeric structures and anionic forms of hydrazoneoxime ligands bearing pyrazolone group (1-4) |
The coordination compounds of nickel(II), copper(II), and cobalt(II) have been synthesized as per general methodology [1,16] as discussed previously (Scheme 3). The metal ion and ligands react in 1:2 molar ratios, where the ligands are attached to metal by using its two N atoms, likealmost all of vic-dioximes act. All of thiscoordinated compounds are colored, amorphous solids, stable at room temperature as well.The discussed complexes are insoluble in commonly used organic solvents, but are soluble in DMF and DMSO. The recommended structures of the synthesized coordination compounds has beendemonstrated inScheme 3that are supported by spectroscopic, FTIR spectral date , and elemental analysis studies.As per the suggested structures, the complexes can have syn- or anti- conformation [28].The magnetic moment (µeff) statistics further favoured the mononuclear structures of the coordinated complexes.The magnetic moment for the nickel(II) complexes are diamagnetic at room temperature, since it is expected due to thed8 and d10 electronic configurations [30].The magnetic moments (µeff)of the copper(II) complexes are 1.63, 1.76, 1.77 and 1.77 BM, respectively, so they are paramagnetic in nature. The cobalt(II) complexes of ligands are paramagnetic and their magnetic moments (µeff) are 2.05, 2.07, 2.08, and 2.09 BM, respectively. The lower figurepossibly due to the anti ferro magnetic interaction between neighboring magnetic centers.
The another chemical environments will assignbetween two (O···H–O)bridge protons in the cis-form, at the same time one in the trans-form. Experience of the H- bond (O···H–O) in the IR , and 1H NMR spectrum, appearing in single frequency in all cases,that indicates the nickel(II) complex is in the anti-form media. On the basis of the above experimental findings , the geometry of the nickel(II) and copper(II) and cobalt(II) complexes are recommended as square-planar[1,16].
The possible tautomeric forms of new nickel(II) and copper(II) and cobalt(II) complexes 1(a-c), 2(a-c), 3(a-c) and 4(a-c) has to be explained inScheme 5. The newly synthesized complexes possibly occurs into four probable tautomeric forms i.e. keto-azo (T1 and T4), keto-hydrazo ( T2),as well as in enol-azo (T3) form.As reported in the literature, utmost stabilized tautomeric form is aketo-hydrazo form (T2) forazopyrazolone dyes.The complexes have an intramolecular hydrogen bonding N-H…O for keto-hydrazone (T2) form and O-H…N for enol-azo (T3) form.These results are consistent with the literature [23,26-29,31].
Scheme 5: Proposed structure for nickel(II), copper(II) and cobalt(II) complexes Click here to View scheme |
Biological activity
The synthesized compounds have been examined for their antimicrobial (antibacterial andanti- fungal)activity.
Antimicrobial activity
The in vitro antimicrobic(S. aureus , B. subtilis , E. coli, P.aeruginosa and antifungal (C. albicans , C. tropicalis, and C. glabrata laboratory isolate) activities of the compounds 1a -4c were evaluated by agar well diffusion method [22]. The results for the antimicrobial study of the tested compounds against the test organisms are illustrated as in Table-9.
Table 9: Antımıcrobıc Actıvıty Of The Synthesızed Compounds By Well Dıffusıon Assay
S.No |
Compounds Tested |
Effective concentration (µg/well) |
Antimicrobic activity of metal complexes [inhibition zone mm] |
||||||
A |
B |
C |
D |
E |
F |
G |
|||
1 |
1a |
150 |
9 |
9 |
10 |
14 |
14 |
14 |
14 |
2 |
1b |
150 |
10 |
9 |
9 |
15 |
14 |
15 |
15 |
3 |
1c |
150 |
8 |
8 |
9 |
13 |
14 |
14 |
14 |
4 |
2a |
150 |
11 |
10 |
10 |
14 |
14 |
14 |
14 |
5 |
2b |
150 |
12 |
11 |
11 |
15 |
15 |
14 |
14 |
6 |
2c |
150 |
8 |
9 |
9 |
12 |
13 |
12 |
12 |
7 |
3a |
150 |
11 |
10 |
10 |
17 |
17 |
18 |
16 |
8 |
3b |
150 |
15 |
14 |
14 |
20 |
19 |
19 |
18 |
9 |
3c |
150 |
8 |
8 |
8 |
15 |
14 |
14 |
14 |
10 |
4a |
150 |
9 |
8 |
8 |
13 |
15 |
15 |
14 |
11 |
4b |
150 |
11 |
10 |
10 |
16 |
16 |
15 |
16 |
12 |
4c |
150 |
8 |
8 |
8 |
14 |
14 |
14 |
14 |
Chloramphenicol |
100 |
— |
— |
— |
30 |
30 |
30 |
30 |
|
Fluconozole |
100 |
28 |
25 |
25 |
— |
— |
— |
— |
A-Candida albicans, B- Candida trophicalis, C- Candida glabrata, D- Staphylococcus aureus, E- Bacillus subtilis, F- Escherichia coli, G-Pseudomonas aeruginosa
Results of the synthesized compounds1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 3c, 4a, 4b, and 4care outlined for antimicrobicactivitywith respect tofourbacteria Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and three fungusesas Candida albicans, Candida tropicalis, and Candida glabrata are illustrated in Table 9.
Antimicrobial activity against “Gram positive”, “Gram-negative” bacteria, and agaist fungus have been seen across all the synthesized compounds.Newly synthesized compounds 3b showed signifant gross broad-spectrum antimicrobial activity, i.e.,against“Gram-positive”,“Gram-negativebacteria”as well as anti fungal.The effective concentration of these active compounds was 150 µg /well.
Conclusion
Investigations into the synthesis of new hydrazoneoxime ligands having pyrazolone group and their metal complexeshave been carried out in this study. The synthesized pyrazolone derivatives of Co(II), Ni(II), andCu(II) complexes were isolated and their structures were characterized using physicochemical techniques.Also, tautomerism in the ligands was investigated by spectroscopic.Chemical propertirs of the complex compounds depend upon Tautomerism, and also physical properties like colour fastness depend on it .The attachment of ligands to the metal ion in a neutral bidentate form with the azomethine nitrogen (C=N) and the carbonyl oxygen (C=O).The calculated magnetic moments of the coordinated complex compounds as 2.92B.M for the nickel(II) and 1.65 B. M for the copper(II) are approximate the spin values only , and proposea square planar geometry for the complexes. The compounds 3b exhibited broad-spectrum antimicrobial activity. Expeditions to explore their potentialities in the future for other biological assays are needed to investigate further. Furthermore, some Co (II) complexes act as potent anti-cancer agents due to their anti-proliferative effects; in this regard, the synthesized compounds should be investigated in the future as well. These complexes can be further explored in the dye/color industry due to the presence of chromophores.
Acknowledgment
We acknowledge to Aydın Adnan Menderes University Scientific Research Foundation for their financial support (Project No: FEF-18022).
Conflict of Interest
The authors declare that they have no conflict of interest.
References
- Wang, X. H; Jia, D. Z.; Liang, Y.J.; Yan, S. L.; Ding, Y.; Chen, L. M.; Shi, Z.; Zeng, M. S.; Liu, G. F.; Fu, L. W.; Lgf-YL-9 induces apoptosis in human epidermoid carcinoma KB cells and multidrug resistant KBv200 cells via reactive oxygen species in dependent mitochondrial pathway, Cancer Lett. 2007, 249, 256-270.
CrossRef - Kimata, A.; Nakagawa, H.; Ohyama, R.; Fukuuchi, T.; Ohta S.; Dohura, K.; Suzuki, T.; Miyata, N.; New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation .J. Med. Chem.2007 , 50 (21), 5053-5056.
CrossRef - Costa, D.; Marques, A.P.; Reis, R.L.; Lima, J.L.F.C.; Fernandes, E.; Inhibition of human neutrophil oxidative burst by pyrazolone derivatives. Free Radical Biol. Med. 2006, 40, 632–640.
CrossRef - Arnost, M.; Pierce, A.; ter Haar, E.; Lauffer, D.;Madden, J.; Tanner, K.; Green, J.; 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta. Bioorg Med Chem Lett. 2010, 20:1661–1664.
CrossRef - Ragavan, R.V.; Vijaykumar, V.; Suchetha, K.N.; Synthesis of some novel bioactive 4-oxy/thio substituted-1H-pyrazol-5(4H)-ones via efficient cross-Claisen condensation. Eur. J. Med. Chem.2009, 44:3852-3857.
CrossRef - Gursoy, A.; Demirayak, S.; Capan, G.; Erol, K.; Vural, K.; Synthesis and preliminary evaluation of new 5-pyrazolinone derivatives as analgesic agents. Eur. J. Med. Chem.2000, 35:359-364.
CrossRef - Castagnolo, D.; Manetti, F.; Radi, M.; Bechi, B.; Pagano, M.; Logu, A.D.; Meleddu, R.; Saddi, M.; Botta, M.; Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: Part 2. Synthesis of rigid pyrazolones. Bioorg. Med. Chem. 2009,17:5716-5721.
CrossRef - Parekh, N.; Maheria, K.; Patel, P.; Rathod, M.; Study on antibacterial activity for multidrug resistance stain by using phenyl pyrazolones substituted 3-amino 1H-pyrazolon (3,4-b) quinoline derivative in-vitro condition. Int. J. Pharm. Tech Res. 2011, 3: 540-548.
- Mariappan, G.; Saha, B.P.; Sutharson, L.; Haldar, A.; Synthesis and bioactivity evaluation of pyrazolone derivatives. Indian Journal of Chemistry B. 2010, 49:1671-1674.
- Manojkumar, P.; Ravi, T.K.; Subbuchettiar, G.; Synthesis of coumarin heterocyclic derivatives with antioxidant activity and in vitro cytotoxic activity against tumour cells. Acta Pharm. 2009, 59:159-170.
CrossRef - Isloor, A.M.; Kalluraya, B.; Shetty, P.; Regioselective reaction: synthesis, characterization and pharmacological studies of some new Mannich bases derived from 1, 2, 4-triazoles. Eur. J. Med. Chem. 2009, 44, 3784- 3787.
CrossRef - Isloor, A.M.; Kalluraya, B.; Rao, M.; Sydnone derivatives: part IV; synthesis of 3-aryl-4-(substituted pyrazolidene hydrazine-4-thiazolyl) sydnones as possible analgesic and anticonvulsant agents. J. Saudi Chem. Soc. 2000, 4: 265- 270.
- Kalluraya, B.; Isloor, A.M.; Shenoy, S.; Synthesis and biological activity of 6-substituted-3-[4-(3-substituted pyrazolidene) hydrazino-4-thiazolyl] coumarins. Indian J. Heterocyclic Chem. 2001, 11: 159-162.
- Sunil, D.; Isloor, A.M.; Shetty, P.; Synthesis, characterization and anticancer activity of 1,2,4-Triazolo [3,4-b]-1,3,4-thiadiazoles on Hep G2 cell lines. Der Pharma Chemica. 2009, 1, 19-26.
- Jensen, B.S.; The synthesis of 1-phenyl-3-methyl-4-acyl-pyrazolones-5. Acta Chem. Scand. 1959, 13, 1668-1670.
CrossRef - Sarıkavaklı, N.; İrez, G.; Synthesis and Complex Formation of Some Novel vic-Dioxime Derivatives of Hydrazones. Turk J Chem. 2005, 29: 107-115.
- Elnagdi, M.H.; Elgemeie, G.E.H.; Abdelaal, F.A.E.; Recent developments in the synthesis of pyrazole derivatives. Heterocyclic. 1985, 23:3121– 53.
CrossRef - Şener, N.; Karcı, F.; Şener, İ.; Serkan, Y.; Synthesis, Absorption Properties and Biological Evaluation of Some Novel Disazo Dyes Derived from Pyrazole Derivatives. Asian J. Chem. 2015, 27: 3003-3012.
CrossRef - Hamama, W.S.; El-Gohary, H.G.; Kuhnert, N.; Zoorob, H.H.; Chemistry of pyrazolinones and their applications. Curr. Org. Chem. 2012, 16,373–399.
CrossRef - Aktan, E.; Ertan, N.; Uyar, T.; Synthesis, characterization and theoretical study of new hetarylazopyrazolone dyes and investigation of their absorption spectra. J.Mol. Struct. 2014,1060, 215-222.
CrossRef - C.Perez;.M.PauliandP;.Bazerque;.ActaBiol.Med.Exp,1990,15,113.
- .K.Harathi;.D. Giribabu;. C.Varadarajulu Naidu;. Phytochemical Evaluation and in Vitro Antibacterial Activity of Sphaeranthus indicus (L.)—An Important Ant jaundice Medicinal Plant;. American Journal of Plant Sciences, 2017, Vol.8 No.5.
- Ertan, N.;Synthesis of some hetarylazopyrazolone dyes and solvent effects on their absorption spectra. Dyes Pigm. 2000, 44, 41-48.
CrossRef - Song, H.; Chen, K.; Tian, H.; Synthesis of novel dyes derived from 1-ethyl-3-cyano-6-hydroxy-4-methyl-5-amino-2-pyridone. Dyes Pigm. 2002,53,257-262.
CrossRef - Sarıkavaklı, N.; Çakıcı, H.T.; Synthesis and Characterization of Co (II), Ni (II), Cu (II) and Zn (II) Complexes of Glyoxime Hydrazone. Asian J. Chem. 2011, 23(3), 1321-1326.
- Seferoglu, Z.; Yalcın, E.; Babur, B.; Seferoglu, N.; Hokelek, T.; Yılmaz, E.; Sahin, E.; Phenylazoindole dyes-Part I: The syntheses, characterizations, crystal structures, quantum chemical calculations and antimicrobial properties. Spectrochim. Acta. 2013,113, 314-324.
CrossRef - Nami, S.A.A.; Husain, A.; Ullah, I.; Self assembled homodinuclear dithiocarbamates: One pot. synthesis and spectral characterization. Spectrochim. Acta Part A. 2014, 118, 380-388.
CrossRef - Aktan, E.; Babür, B.; Seferoğlu, Z.; Hökelek, T.; Şahin ,E.; Synthesis and structure of a novel hetarylazoindole dye studied by X-ray diffraction, FT-IR, FT-Raman, UV–vis, NMR spectra and DFT calculations. J. Mol. Struct. 2011, 1002:113–120.
CrossRef - Nami, S.A.A.; Siddiqi, K.S.; Unique keto-enol tautomerism in transition metal complexes of cyanoimidodithiocarbonate. J. Chem. Res.2006, 563-565.
CrossRef - Pettinari, C.; Marchetti, F.; Cingolani, A.; Gindulyte, A.; Massa , L.; Rossi, M.; Caruso, F.; Syn-anti Conversion in octahedral bis (beta-diketonato) diorganotin (IV) derivatives containing fluorinated 4-acyl-5-pyrazolonato donors. Eur. J. Inorg. Chem. 2001, 8: 2171-2180.
CrossRef
This work is licensed under a Creative Commons Attribution 4.0 International License.